Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cannabinoid therapy in epilepsy

Billakota, Santoshia; Devinsky, Orrinb; Marsh, Ericc,d,e

doi: 10.1097/WCO.0000000000000660
SEIZURE DISORDERS: Edited by Philippe Ryvlin
Buy
SDC

Purpose of review To review the history, pharmacology, and clinical science of cannabidiol (CBD) in the treatment of epilepsy.

Recent findings Phase III randomized controlled trials and prospective open label trials have provided efficacy and safety data for the use of CBD in pediatric onset severe epilepsies. The product that was studied in the vast majority of these published trials, Epidiolex (>99% of CBD and <0.10% Δ9-tetrahydrocannabinol (THC); GW pharmaceuticals, Cambridge, UK), has now been FDA approved based on this published data.

Summary Identification of CBD, Δ9-THC, and the endocannabinoid system in the mid-20th century has led to advancement of cannabis-based therapies for epilepsy. Based on clinical trial data, Epidiolex is the first CBD medication approved by a national regulatory agency (US Food and Drug Administration for Dravet and Lennox Gastaut syndrome). Approval of CBD as a treatment for these rare and severe pediatric-onset epilepsy syndromes is an important milestone, but the complete spectrum of use of cannabis-derived products, and the use of CBD for other epilepsy syndromes remains to be determined.

aNYU Langone Comprehensive Epilepsy Center and NYU Langone School of Medicine, New York, New York

bSaint Barnabas Institute of Neurology and Neurosurgery, Livingston, New Jersey

cDivision of Child Neurology, Children's Hospital of Philadelphia

dDepartment of Neurology

eDepartment of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Correspondence to Santoshi Billakota, MD, 223 East 34th St, New York, NY 10016, USA. Tel: +1 646 558 0800; fax: +1 646 754 9800; e-mail: santoshi.billakota@nyulangone.org

Copyright © 2019 Wolters Kluwer Health, Inc. All rights resereved.